AANEM Will Preview New Myasthenia Gravis Treatments
The 2026 MGFA Scientific Session will highlight advancements in targeted therapies for myasthenia gravis.
Updated on Sept. 22, 2026 in Alzheimer’s
Live Poll
Do you trust that new medical treatments are made accessible to patients in your area?
The 2026 MGFA Scientific Session at the AANEM meeting will focus on the expanding landscape of targeted myasthenia gravis therapies. This presentation will examine evolving treatment options as medical researchers develop more diverse approaches to patient care.
Why it matters
As the number of available myasthenia gravis treatment options grows, clinicians must navigate complex decisions regarding therapy sequencing and patient transitions. Establishing effective strategies for managing these new options is critical for improving long-term outcomes.
Researchers are investigating diverse therapeutic mechanisms, including BAFF/APRIL-targeted approaches and CD19-directed CAR T-cell therapies. The ADAPT SERON phase 3 trial previously assessed intravenous efgartigimod for patients with specific antibody-seronegative conditions.
The players
MGFA
The Myasthenia Gravis Foundation of America is a national organization dedicated to supporting research and patient advocacy for those living with the disease.
AANEM
The American Association of Neuromuscular & Electrodiagnostic Medicine is a professional association focused on the improvement of patient care through education and research.
The details
The treatment landscape is diversifying beyond standard care as scientists refine B cell-depleting monoclonal antibodies and cellular therapies. Clinicians are increasingly focused on individualized assessment strategies to match these advanced therapies to specific patient needs.
Timeline
The MGFA Scientific Session will take place at the AANEM meeting in 2026.
The Big Picture
This session builds upon the clinical foundation set by the ADAPT SERON phase 3 trial by exploring how newer classes of medications integrate into standard practice. It marks a broader shift in neuromuscular medicine toward highly targeted, individualized therapeutic regimens.
The expansion of treatment options may provide new avenues for patients who previously had limited therapy pathways available. Patients should discuss potential transitions and individualized care plans with their neurologists to determine which emerging therapies might be appropriate.
The takeaway
The increasing complexity of myasthenia gravis treatments highlights the need for careful coordination between specialists and patients. Staying informed about clinical session findings can help patients and providers make more effective, data-driven decisions about their care paths.
Further reading
For more information on the latest research and clinical standards, visit the Alzheimer’s section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that new medical treatments are made accessible to patients in your area?
